Search results: (10000)
News Comparison of Enoxaparin and Unfractionated Heparin in Hospitalized Patients in Terms of Clinical and Cost Effectiveness
Thromboembolic disease represents one of the severe complications in hospitalized patients. Low molecular weight and unfractionated heparin are most commonly used during hospitalization as part of pharmacological thromboprophylaxis. An extensive study conducted in the United States evaluated the clinical and cost-effectiveness and safety of both therapy modalities in hospitalized patients at risk of thromboembolic disease.
News Treatment with Dupilumab in Severe Corticosteroid-Dependent Bronchial Asthma – A Case Study
We present the case of a 36-year-old woman with severe corticosteroid-dependent asthma with numerous comorbidities and complications due to long-term systemic corticosteroid therapy. Significant improvements in quality of life, asthma control, regression of skin changes in atopic dermatitis, and reduction in methylprednisolone consumption for this patient were only achieved after the initiation of biological treatment. Dupilumab, a monoclonal antibody against the α subunit of the receptor for interleukins IL-4 and IL-13, which is approved for the treatment of severe refractory eosinophilic bronchial asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis, was indicated in her treatment.
News How to Detect COPD Early in Primary Care?
Chronic obstructive pulmonary disease (COPD) can be present even in individuals without obvious subjective symptoms, or the emerging symptoms may be overlooked by both the patient and the doctor due to their very gradual development. So, what is the path to early detection of COPD in primary care, and how can this disease be distinguished from others accompanied by similar manifestations?
News News in COPD Treatment Recommendations in a Nutshell
We present an overview of the most important changes in the annually updated recommendations of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
News STADA Brings Innovative Drug for Treatment of Advanced Parkinson's Disease to Czech Republic
STADA PHARMA CZ is introducing a new system for continuous delivery of 3 active substances for the treatment of advanced stages of Parkinson's disease (PD) to the Czech market. It is one of the major innovations in the care of PD patients in the last two decades. The drug, which STADA acquired the rights to in 2020, had already been introduced in the Nordic countries where this treatment is successfully underway. In the Czech Republic, it has been fully covered since April 1, 2022.
News Even a Single Epileptic Seizure is Too Much
Focal epileptic seizures resistant to pharmacotherapy represent an ongoing unmet medical need.
News Insufficiently Controlled Epilepsy Reduces Quality and Length of Life
The effects of uncontrolled epilepsy far exceed the moment of a seizure, having a substantial impact on the psychological and physical well-being of patients. These individuals often sustain injuries during seizures, leading to reduced mobility, a higher risk of associated diseases, and premature death.
News Can Erdostein Help in Treating Infections Related to Biofilm Formation?
One of the reasons for the very difficult treatment of diseases caused by resistant bacterial strains is the significant ability of these infection-causing agents to form biofilms. What exactly is a biofilm? Which bacteria are likely to form it, and how can erdostein help in the fight against it?
News Administration of Erdosteine After Severe Course of COVID-19 in the Early Period After Patient Discharge From Medical Facility
Erdosteine is a mucomodulatory drug used in the therapy of various acute and chronic respiratory diseases. Its mechanism of action is considered complex based on available evidence, encompassing antioxidant and antibacterial effects along with its mucolytic effect. Two clinical studies assessed changes in respiratory distress parameters and quality of life in patients taking this medication in the early period after discharge from medical facilities where they were hospitalized for severe COVID-19 (respiratory failure, pneumonia).
News Monocyte Distribution Width as an Early Indicator of Sepsis in ICU Patients
Authors of a Franco-Spanish study propose using the monocyte distribution width along with leukocyte count as a screening test to refine the early diagnosis of sepsis in intensive care unit (ICU) patients based on their research findings.
News Curative Potential of Neoadjuvant Denosumab in the Treatment of Giant Cell Spinal Tumor? A Case Study
Portuguese authors present a case study of a young woman diagnosed with a giant cell spinal tumor who achieved complete histological remission following denosumab treatment.
News Prevention of Skeletal Events in the Therapy of Patients with Advanced Prostate Cancer
Prostate cancer most commonly forms metastases in the bones. In patients with this advanced disease, skeletal events occur, negatively affecting their quality of life. Zoledronic acid and denosumab are used to prevent their occurrence, and their results in this indication were evaluated and compared in the cited study below.
News The Immune System in the Pathophysiology of ITP
From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that the etiology of this disease is very complex and involves both antibody and cellular immunity.
News Over 10 Years of Experience with TPO-RA in the Treatment of Immune Thrombocytopenia
Medications from the group of thrombopoietin receptor agonists (TPO-RA) have become an integral part of the therapy for patients with immune thrombocytopenia (ITP) over the past more than 10 years. Their administration represents a new approach compared to the previous, long-established treatment, and has significantly changed the prognosis of the disease in many patients.
News Potential of Enoxaparin to Maintain A-V Shunt Patency According to the SEP Protocol
A newly published study by authors from Singapore focused on the ability of the SEP protocol – short-term low-dose enoxaparin administration based on body weight – to maintain the patency of an arteriovenous (A-V) shunt after recurrent thrombosis.